Drug treatment for mood disorders in pregnancy

Current Opinion in Psychiatry

Volumn 24, Issue 1, 2011, Pages 34-40

  Gentile, Salvatore ^a  

^a ASL Salerno   (Italy)

Author keywords

perinatal teratogenicity; pregnancy; psychotropics; structural teratogenicity

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; LITHIUM; MOOD STABILIZER; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ARTICLE; AUTISM; BIPOLAR DISORDER; DEVELOPMENTAL DISORDER; DRUG EXPOSURE; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; HUMAN; MOOD DISORDER; PERINATAL PERIOD; PREGNANCY; PREGNANCY DIABETES MELLITUS; RISK ASSESSMENT; TERATOGENICITY; THIRD TRIMESTER PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; DRUG TOXICITY; FEMALE; HUMANS; INFANT, NEWBORN; MOOD DISORDERS; PERINATAL CARE; PREGNANCY; PRENATAL CARE; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOTROPIC DRUGS; RISK ASSESSMENT;

EID: 78650542960     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e3283413451     Document Type: Article

References (68)

1. Brand SR, Brennan PA. Impact of antenatal and postpartum maternal mental illness: how are the children? Clin Obstet Gynecol 2009; 52:441-455.
2. Hay DF, Pawlby S, Waters CS, et al. Mothers antenatal depression and their childrens antisocial outcomes. Child Dev 2010; 81:149-165.
3. Skouteris H, Wertheim EH, Rallis S, et al. Depression and anxiety through pregnancy and the early postpartum: an examination of prospective relationships. J Affect Disord 2009; 113:303-308.
4. Viguera AAC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007; 164:1817-1824.
5. Lee HC, Lin HC. Maternal bipolar disorder increased low birthweight and preterm births: a nationwide population-based study. J Affect Disord 2010; 121:100-105.
6. Goodman JH. Womens attitude, preferences, and perceived barriers to treatment for perinatal depression. Birth 2009; 36:60-69.
7. Bennett IM, Marcus SC, Palmer SC, Coyne JC. Pregnancy-related discontinuation of antidepressants and depression care visits among Medicaid recipients. Psychiatr Serv 2010; 61:386-391.
8. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005; 28:137-152.
9. FDA Public Health Advisory. Paroxetine. http://69.20.19.211/cder/drug/ advisory/paroxetine200512.htm. [Accessed 10 May 2008]
10. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16:1075-1085.
11. ReisM, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010. [Epub ahead of print]
12. Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009; 54:242-246.
13. Diav-Citrin O, Schechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Br J Clin Pharmacol 2008; 66:695-705.
14. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. Br Med J 2009; 339:b3569. doi: 10.1136/bmj.b3569.
15. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotoninreuptake inhibitors and the risk of birth defects. New Engl J Med 2007; 356:2675-2683.
16. Gentile S. Escitalopram use during pregnancy. Navigating toward international guidelines and the real world. Clin Drug Invest 2008; 28:735-739.
17. Gentile S, Bellantuono C. SSRI-exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. J Clin Psychiatry 2009; 70:414-422.
18. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158:1728-1730.
19. Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Def Res Part B 2008; 83:68-76.
20. Loughhead AM, Fisher AD, Newport DJ, et al. Antidepressants in amniotic fluid: another route of fetal exposure. Am J Psychiatry 2006; 163:145-147.
21. US Food and Drug Authority. FDA Medwatch drug alert on Effexor and SSRIs. 2004. www.fda.gov/MEDWATCH/SAFETY/2004/efexxor-dear-hcp-june.pdf. [Accessed 13 April 2008]
22. Health Canada. Health Canada advises of potential serious adverse effects of SSRIs and other antidepressants on newborns [advisory]. Ottawa: Health Canada; 2004. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/-2004/2004- 44-e.html. [Accessed 13 April 2008]
23. Levin R. Neonatal adverse events associated with in utero SSRI/SNRI exposure. www.fda.gov/ohrms/dockets/AC/04/slides/2004-4050S1-11-Levin. ppt. [Accessed 15 February 2008]
24. Gentile S. SRI-induced perinatal complications. Paediatr Drugs 2007; 9:97-106.
25. FDA ALERT [7/2006]: Increased risk of neonatal persistent pulmonary hypertension. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/DrugSafetyInformationforHeathcare Professionals/ucm085313.htm. [Accessed 21 April 2010]
26. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med 2006; 354:579-587.
27. Källén B, Otterblad-Olausson P. Maternal use of selective re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008; 17:801-806.
28. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and the risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009; 18:246-252.
29. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365:482-487.
30. Gentile S. On categorizing gestational, birth, and neonatal complications following late in utero exposure to antidepressants. The Prenatal Antidepressant Exposure Syndrome. CNS Spectr 2010; 15:167-185.
31. Lund N, Pedersen LH, Henriksen TB. Selective reuptake inhibitor exposure in utero and pregnancy outcome. Arch Pediatr Adolesc Med 2009; 163:949-954.
32. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007; 27:607-613.
33. Yacoby S, Ornoy A. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review. Isr J Psy Relat Sci 2008; 45:95-106.
34. Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 2010; 44:99-108.
35. Newport DJ, Viguera AC, Beach AJ, et al. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry 2005; 162:2162-2170.
36. Gentile S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipol Disord 2006; 8:207-220.
37. Nguyen HT, Sharma HT, McIntyre RS. Teratogenesis associated with antibipolar agents. Adv Ther 2009; 26:281-294.
38. Mawer G, Briggs M, Baker GA, et al. Liverpool and Manchester Neurodevelopment Group. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure 2010; 19:112-119.
39. Vajda FJ, Hitchcock AA, Graham J, et al. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010; 51:805-810.
40. Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009; 27:993-1002.
41. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008; 70:2152-2158.
42. Dolk H, Jentinik J, Loane M, et al. EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008; 71:714-722.
43. Sabers A, Tomson T. Managing antiepileptic drugs during pregnancy and lactation. Curr Opin Neurol 2009; 22:157-161.
44. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 2009; 50:2130-2139.
45. Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008; 28:279-288.
46. McKenna K, Koren G, Tetelbaum M. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005; 66:444-449.
47. Coppola L, Russo LJ, Kwarta RF Jr, et al. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 2007; 30:247-294.
48. Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotics during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007; 164:1214-1220.
49. Babu GN, Desai G, Tippeswany H, Chandra PS. Birth weight and use of olanzapine during pregnancy: a prospective comparative study. J Clin Psychopharmacol 2010; 30:331-332.
50. Lin HC, Chen IJ, Chen YH, et al. Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res 2010; 116:55-60.
51. Feizo MS, Poursharif B, Korst LM, et al. Symptoms and pregnancy outcomes associated with extreme weight loss among women with hyperemesis gravidarum. J Womens Health (Larchmt) 2009; 18:1981-1987.
52. Davies GA, Maxwell C, McLeod L, et al. Obesity in pregnancy. J Obstet Gynaecol Can 2010; 32:165-173.
53. Davson SI. Long-term risk of malignant neoplasm associated with gestational glucose intolerance. Cancer 2004; 100:149-155.
54. Amselem C, Puigdollers A, Azpiroz F, et al. Constipation: a potential cause of pelvic floor damage? Neurogastroenterol Motil 2010; 22:150-153.
55. National Institute of Diabetes, Digestive, and Kidney Diseases. Constipation. http://digestive.niddk.nih.gov/ddiseases/pubs/constipation/. [Accessed 24 April 2004]
56. Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population- based study. Br J Psychiatry 2008; 192:338-343.
57. Warburton W, Hertzman C, Oberlander TF. A register study of impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 2010; 121:471-479.
58. Omori IM, Watanabe N, Nakagawa A, et al. Fluvoxamine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2010: CD006114.
59. Dannon PN, Iancu I, Lowengrub K, et al. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol 2007; 30:326-334.
60. Watanabe N, Omori IM, Nakagawa A, et al., MANGA (Meta-Analysis of New Generation Antidepressants) Study Group. Safety reporting and adverseevent profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010; 24:35-53.
61. Hewett K, Gee MD, Krishen A, et al. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2010; 24:1209-1216.
62. Figueroa R. Use of antidepressants during pregnancy and the risk of attentiondeficit/hyperactivity disorder in the offspring. J Dev Behav Pediatr 2010; 31:641-648.
63. Edwards IR, Biriell C. Harmonization in pharmacovigilance. Drug Saf 1994; 10:93-102.
64. Meador KJ, Baker GA, Browning N, et al. Cognitive functions at 3 years after fetal exposure to antiepileptic drugs. New Engl J Med 2009; 360:1597-1605.
65. Bromley RL, Mawer G, Clayton-Smith J, Baker GA, Liverpool and Manchester Neurodevelopment Group. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008; 71:1923-1924.
66. Gentile S. Antipsychotic therapy during early and late pregnancy: a systematic review. Schizophrenia Bull 2010; 36:518-544.
67. Gentile S. Contributing factors to weight gain during long-term treatment with second-generation antipsychotics: a systematic appraisal and clinical implications. Obesity Rev 2009; 10:527-542.
68. Gentile S. Long term atypical antipsychotics treatment and risk of weight gain: a literature analysis. Drug Saf 2006; 29:303-319.